01What is CBD?

CBD is a phytocannabinoid found in hemp. Unlike THC, it is not psychoactive and does not cause euphoria. It is found in the form of sublingual oil, capsules, infusions, or topicals.

02How CBD works in the body

CBD modulates the endocannabinoid system (ECS), a network of receptors (CB1, CB2) involved in homeostasis: mood, sleep, pain, appetite, immunity. It also acts on other targets: TRP channels (especially TRPV1, involved in skin and pain) and serotonin 5-HT1A receptors, probably responsible for its anxiolytic effect.

Key takeaway: CBD does not act as a direct medication for a single symptom. It modulates several upstream pathways, which explains why its effects are often gradual rather than immediate.

03Stress and anxiety: what the new data shows

A 2025 open trial using 30 mg/day of a CBD-rich full-spectrum product also showed a significant reduction in anxiety and mood in participants.

04Sleep

By reducing stress and certain pains, CBD can indirectly contribute to more restorative sleep. A 2024 review of 21 recent studies on cannabinoids and sleep, however, noted that the evidence base does not yet match the scale of public consumption, and that formulations combining CBD and THC show more promising results than CBD alone for this specific use.

We have dedicated a comprehensive article to this topic, with details of the most recent clinical trials.

05Pain and inflammation: an important re-evaluation

This is one of the most significant updates for 2026, and we prefer to give it to you honestly rather than keeping silent about it.

CBD continues to be studied for its anti-inflammatory properties at the cellular level, but the translation of these mechanisms into measurable clinical benefit for chronic pain remains, to date, more uncertain than the wellness market suggests.

06Cardiovascular health

Conversely, this is one of the avenues that is most clearly strengthening. A 2026 systematic review published in the Journal of Cannabis Research, combining 4 randomized controlled trials (120 participants), found that oral CBD reduced systolic blood pressure compared to placebo, particularly during stress situations and during sleep.

This is a stronger confirmation than the simple isolated pilot trial cited in the past: we are moving from a preliminary signal to the beginning of a consensus across several independent trials.

07Skin and cosmetics: the antioxidant pathway

A study published in 2026 in the journal Antioxidants (Medical University of Białystok and Ruđer Bošković Institute, Croatia) tested CBD and CBG on human melanocytes and melanoma cells exposed to UVA. Both cannabinoids reduced oxidative stress, lipid peroxidation, and inflammatory signaling (NF-κB), and improved the skin's natural antioxidant defenses (glutathione, superoxide dismutase) by 10 to 40% depending on the markers.

08Epilepsy and neuroprotection

Purified CBD (Epidiolex) remains, to date, the only FDA-approved CBD-based drug for certain severe forms of childhood epilepsy. Long-term follow-up data from the expanded access program show sustained seizure reduction for up to 144 weeks of treatment, for forms of epilepsy beyond the initially approved indications.

In the field of brain aging, research published in 2026 explores the hypothesis that CBD could slow down certain processes related to Alzheimer's disease by mitigating brain inflammation. These works are still preliminary and are not intended to replace neurological monitoring.

09CBD and cancer: where research stands

Interest in CBD in oncology continues to grow, but preclinical data (cells, animals) must be clearly distinguished from clinical evidence (human patients). On the latter point, no robust evidence currently shows that CBD cures cancer.

Key message, unchanged since our previous edition: CBD can be considered, under medical supervision, as a support for certain symptoms (pain, sleep, mood) in patients undergoing treatment, never as a replacement for oncological therapy. Any use must be discussed with the treating oncologist, particularly due to the risks of drug interactions.

10Safety and interactions

A recent randomized clinical trial tested low-dose full-spectrum CBD in adults living with HIV, on long-term antiretroviral therapy with an undetectable viral load. CBD was well tolerated, with no significant negative effects on liver function, kidney function, or HIV-related markers—a reassuring signal for people on complex treatments, although medical advice remains essential before any combination.

That said, caution remains advised at high doses and in the long term: an elevation of liver enzymes has been reported in a minority of participants in several clinical trials, particularly when other treatments are taken concomitantly. Medical monitoring is recommended in case of prolonged daily use or polymedication.

11Dosage and precautions

• Start low (5 to 10 mg/day), gradually increase according to perceived effects.
• Adapt the form: sublingual for a rapid effect, capsule for precise and prolonged dosage, infusion for a gentle effect, topical for local action.
• Keep in mind the inverted U-curve observed for anxiety: a higher dose is not automatically more effective.
• Most common side effects: dry mouth, mild drowsiness, drop in blood pressure.

12Legality and quality

In Switzerland, CBD products are legal if the THC content of the finished product remains below 1%. In the European Union, most countries align with a threshold of 0.3%, with varying national regulations. Always prioritize products tested in independent laboratories, with available certificates of analysis.

13Future prospects: what might matter tomorrow

14Frequently asked questions

15Explore further

Cannabinoid guides

Our collections

Blog articles

This article contains general information for educational purposes and does not replace the advice of a healthcare professional. CBD is not a medicine and is not intended to treat, cure, or prevent any disease. Consult a healthcare professional, especially in cases of pregnancy, breastfeeding, chronic illness, or medication use.